ProKidney (PROK) Stock Forecast & Price Target

$1.70 -0.45 (-20.98%)

(As of 11/15/2024 ET)

ProKidney - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 5 Analyst Ratings

Sell
0

Hold
3

Buy
2

Based on 5 Wall Street analysts who have issued ratings for ProKidney in the last 12 months, the stock has a consensus rating of "Hold." Out of the 5 analysts, 3 have given a hold rating, and 2 have given a buy rating for PROK.

Consensus Price Target

$4.50
165.49% Upside

According to the 5 analysts' twelve-month price targets for ProKidney, the average price target is $4.50. The highest price target for PROK is $6.00, while the lowest price target for PROK is $3.00. The average price target represents a forecasted upside of 165.49% from the current price of $1.70.

Get the Latest News and Ratings for PROK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ProKidney and its competitors.

PROK Analyst Ratings Over Time

Type	Current Forecast 11/16/23 to 11/15/24	1 Month Ago 10/17/23 to 10/16/24	3 Months Ago 8/18/23 to 8/17/24	1 Year Ago 11/16/22 to 11/16/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	1 Buy rating(s)	2 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$4.50	$4.50	$4.33	$15.50
Forecasted Upside	165.49% Upside	130.77% Upside	80.56% Upside	1,160.16% Upside
Consensus Rating	Hold	Hold	Hold	Buy

This company will win the AI race (Ad)

Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

PROK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PROK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ProKidney Stock vs. The Competition

Type	ProKidney	Medical Companies	S&P 500
Consensus Rating Score	2.40	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	109.30% Upside	26,221.50% Upside	8.88% Upside
News Sentiment Rating	Positive News See Recent PROK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/30/2024	JPMorgan Chase & Co. 3 of 5 stars		Initiated Coverage	Neutral
9/10/2024	Guggenheim 3 of 5 stars	V. Divan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00	+151.05%
9/4/2024	Bank of America 4 of 5 stars		Lower Target	Neutral ➝ Neutral	$4.00 ➝ $3.00	+25.00%
6/10/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$15.00 ➝ $6.00	+112.77%
3/7/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Equal Weight	$3.00	+77.51%
7/24/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$16.00	+40.47%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 08:33 PM ET.

PROK Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for ProKidney is $4.50, with a high forecast of $6.00 and a low forecast of $3.00.
: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ProKidney in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PROK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PROK, but not buy additional shares or sell existing shares.
: According to analysts, ProKidney's stock has a predicted upside of 165.49% based on their 12-month stock forecasts.
: ProKidney has been rated by research analysts at Bank of America, Guggenheim, and JPMorgan Chase & Co. in the past 90 days.
: Analysts like ProKidney less than other "medical" companies. The consensus rating for ProKidney is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PROK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

[Urgent] Starlink Set For The Largest IPO In History? (Ad)

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.

Click here now for the urgent details on this hidden play.

This page (NASDAQ:PROK) was last updated on 11/15/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProKidney (PROK) Stock Forecast & Price Target